Single-cell genomic analysis has shown that mutations in the KRAS oncogene co-opt a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells, initiating pancreatic ductal adenocarcinoma, Chinese researchers reported in the November 3, 2020, edition of Nature Cancer.
LONDON – Clinical genomics specialist Congenica Ltd. has raised $50 million in a series C round that will enable it to extend beyond its roots in rare disease diagnosis to personalized medicine in cancer, and health and wellness, while expanding its geographical reach.
Yantai, China-based biologics developer Remegen Ltd. launched the biggest pre-revenue biotech IPO in Hong Kong this year by raising HK$3.99 billion ($514.5 million) on Nov 9. With this IPO, Remegen’s CEO Jianmin Fang told BioWorld in an exclusive interview, the company aims to take its assets abroad.
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: 4D, Acepodia, Advaxis, Affimed, Agenus, Alkermes, Alx, Amgen, Beam, Bioinvent, Checkpoint, Codiak, Genocea, Huya, Kleo, Oncolytics, Oncosec, Rubius, Transgene, Vigeo, Windmil.
Japanese researchers have developed a new organoid biobank with which to identify molecular subtypes of rare gastroentero-pancreatic neuroendocrine neoplasms using genotype-phenotype mapping, they reported in the November 6, 2020, online edition of Cell.
RSS
